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GlycolysisAdenine nucleotide translocase (ANT), a mitochondrial protein that facilitates the exchange of ADP and ATP
across the mitochondrial inner membrane, plays an essential role in cellular energy metabolism. Human ANT
presents four isoforms (ANT1-4), each with a speciﬁc expression depending on the nature of the tissue, cell
type, developmental stage and status of cell proliferation. Thus, ANT1 is speciﬁc to muscle and brain tissues;
ANT2 occurs mainly in proliferative, undifferentiated cells; ANT3 is ubiquitous; and ANT4 is found in germ
cells. ANT1 and ANT3 export the ATP produced by oxidative phosphorylation (OxPhos) from themitochondria
into the cytosol while importing ADP. In contrast, the expression of ANT2, which is linked to the rate of
glycolytic metabolism, is an important indicator of carcinogenesis. In fact, cancers are characterized by major
metabolic changes that switch cells from the normally dual oxidative and glycolytic metabolisms to an almost
exclusively glycolytic metabolism. When OxPhos activity is impaired, ANT2 imports glycolytically produced
ATP into the mitochondria. In the mitochondrial matrix, the F1F0-ATPase complex hydrolyzes the ATP,
pumping out a proton into the intermembrane space. The reverse operations of ANT2 and F1F0-ATPase under
glycolytic conditions contribute to maintaining the mitochondrial membrane potential, ensuring cell survival
and proliferation. Unlike the ANT1 and ANT3 isoforms, ANT2 is not pro-apoptotic and may therefore
contribute to carcinogenesis. Since the expression of ANT2 is closely linked to the mitochondrial bioenergetics
of tumors, it should be taken into account for individualizing cancer treatments and for the development of
anticancer strategies. This article is part of a Special Issue entitled: Bioenergetics of Cancer.; ATPsynβ, β subunit of the Fl
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ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Glycolysis replaces oxidative phosphorylation in cancer cells
In normal cells, energy homeostasis is ensured through at least
three metabolic pathways, i.e. glycolysis, lipogenesis and the
tricarboxylic acid (TCA) cycle, all of which are closely linked to the
biosynthesis of amino acids and nucleotides. Although normal cells
use a variety of energy sources, glucose is the key energy source for
cell growth. Glucose, taken up by the glucose transporter system, is
converted to pyruvate through the glycolytic pathway [1,2]. The
pyruvate, which is then converted to acetyl-CoA by pyruvate dehydro-
genase, serves as a substrate for the TCA cycle in mitochondria. Themitochondria generate ATP through the TCA cycle and the oxidative
phosphorylation (OxPhos). The OxPhos mechanism consists of a
respiratory chain comprising of three non-reversible proton pumps
(NADH dehydrogenase, ubiquinol cytochrome c reductase, and cyto-
chrome c oxidase), an enzyme complex not involved in protonpumping
(succinate dehydrogenase), and a reversible proton pump (F1F0-ATP
synthase), which uses the energy of the proton gradient across the
membrane to synthesize ATP [3]. The mitochondrial ATP produced is
exported to the cytosol by adenine nucleotide translocase (ANT)
(Fig. 1A). The respiratory complexes, F1F0-ATP synthase, and some
proteins functionally bound with it in the mitochondrial inner
membrane, formevenmore complicated structures, or supercomplexes,
which promote faster diffusion of substrates or create a tunnel effect in
enzymatic reactions [4]. According to Peter Mitchell's chemiosmotic
theory, the energy-rich intermediate of OxPhos is the proton gradient
(ΔμH+) across the mitochondrial inner membrane. The driving force is
deﬁned as the proton motive force (Δp), consisting of an electrical
component (ΔΨm) and a chemical component (ΔpHm) [5]. The
stoichiometric efﬁciency of OxPhos is determined by the P/O ratio
which deﬁnes the relationship between ATP synthesis and oxygen
consumption. Both the rate and the efﬁciency of OxPhos are complex-
Fig. 1. Models indicating the role of ANT isoforms in oxidative phosphorylation and glycolysis. A. ANT1 and ANT3 mediate mitochondrial ATP synthesis in non-tumoral cells.
Inorganic phosphate (Pi) is transported across the mitochondrial inner membrane (MIM) into the mitochondrial matrix by the mitochondrial phosphate carrier (PiC). F1F0-ATPase
combines Pi and ADP to form ATP, which is then exchanged for ADP across the MIM by ANT1 or ANT3. The whole reaction is driven by a proton gradient maintained mainly by the
respiratory chain. B. Aerobic glycolysis leads to defectivemitochondrial ATP production in tumoral cells. Themitochondrial hexokinase isoform, HK II, generates ATP from glucose 6-P
(G6P) produced by the cytoplasmic hexokinase, HK. The ATP4­, imported into mitochondria across the MOM through the voltage-dependent anion channel (VDAC), and then across
the MIM by the ANT2 isoform, contibutes to the maintenance of the mitochondrial membrane potential (ΔΨm). The hydrolysis of imported glycolytic ATP4­ by the F1 component of
ATP synthase leads to (i) the release of ADP3­ in the mitochondrion with the gain of a negative charge on the matrix side; and (ii) the ejection of a proton into the intermembrane
space through the F0 component.
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respiratory chain, i.e. the NADH+H+/NAD+ ratio, and the membrane
potential (ΔΨm), through the interaction of allosteric effectors such as
ATP or ADP, i.e. the ATP/ADP ratio, with respiratory chain complexes.
Active transport of cations or anions across the membrane also
decreases Δp, stimulating the three proton pumps and consequently
the mitochondrial respiration. In mitochondria, electrogenic transport,
involving the uniport uptake of Ca2+ by the calcium carrier and of ADP3-
through antiport exchange between ATP4- and ANT, decreases ΔΨm.
The electroneutral symport uptake of the negatively chargedphosphate,
together with an H+ by the phosphate carrier, decreases ΔpH, and the
exchange of mitochondrial aspartate against glutamate and an H+ by
the aspartate/glutamate carrier decreases Δp [6].
In most cancer cells, the rate of glucose uptake is higher and the
mitochondrial oxidative phosphorylation is lower than in healthy
cells [7]. This metabolic re-programming triggers a cascade of events
in tumor cell physiology [8]. Increased glycolytic activity in cancer
cells may be due to mitochondrial defects or adaptation to a hypoxic
tumoral microenvironment [9]. The metabolism of glucose to lactate
persists even in aerobic conditions, known as the ‘Warburg effect’,
suggesting that the metabolic shift is highly regulated in tumor cells.
This metabolic switch affects all the factors involved in OxPhos
regulation, i.e. the P/O, NADH+H+/NAD+, ADP/ATP ratios and Δψm
[10–12]. Thus, although glycolytic ATP synthesis may be sufﬁcient for
cell growth, cancer cells need to maintain the Δψm and mitochondrial
homeostasis for Ca2+ exchange, ionic transport and the operation of
metabolite pathways.
ANT, a mitochondrial inner membrane protein, is essential to the
metabolic adaptation of cancer cells during tumoral development. Of
the four ANT isoforms found in humans, ANT2 is particularly involved
in the process of maintaining mitochondrial Δψm and preventing
apoptosis.
2. ANT regulates oxidative phosphorylation in normal cells
Adenine nucleotide translocase (ANT) is the unique catalyst of
ADP/ATP exchanges across the mitochondrial inner membrane. It wasthe ﬁrst member of the large mitochondrial carrier family to be
isolated, reconstituted into liposomes, cloned, and crystallized in the
form of a complex with its speciﬁc inhibitor carboxyatractyloside
[13,14]. ANT, the most abundant protein of the mitochondrial inner
membrane, comprises 300–320 amino acid residues forming six
transmembrane helices. The functional unit of ANT, a homodimer, acts
as a gated pore channeling single molecules of ADP and ATP [6].
During the transport of these molecules, ANT takes up a conformation
oriented toward the cytoplasm (c-conformation) or toward the
mitochondrial matrix (m-conformation) [15]. Atractyloside and
carboxyatractyloside are speciﬁc inhibitors of ANT that act by ﬁxing
the c-conformation, whereas bongkrekic acid (BKA) inhibits ANT by
ﬁxing the m-conformation.
Although ANT is implicated in basal proton leaks [16] and in
inducible proton leaks [17], the translocase is highly selective of the
adenine nucleotide. Thus, ANT plays an essential role in cell
bioenergetics by regulating the ADP/ATP ratio in mitochondrial
oxidative phosphorylation.
3. The human genome encodes four ANT isoforms
The human genome presents four ANT isoforms encoded by the
genes (ANT1-4) [18] (Table 1). ANT1, ANT2 and ANT3 are structurally
similar, each gene possessing four exons, a 1.4 kb cDNA; the peptidic
sequences of the three proteins encoded are about 90% identical. In
contrast, the protein encoded by ANT4 shares 66–68% identical amino
acids with the other three isoforms [19], this lower homology being
explained by the presence of two additional exons. Each ANT isoform
possesses a speciﬁc expression depending on cell type, nature of
tissue, developmental stage and status of cell proliferation. The
regulatory sequences in the 5′ region differ among the ANTs and some
speciﬁc motifs have been studied (Table 1). Most of the data
concerning the expression of ANTs depend on mRNA quantiﬁcations,
correlated with protein measurements. However, the results are
subject to caution since the speciﬁcity of ANT isoforms is difﬁcult to
establish because of the high incidence of identical amino acids in
these transmembrane proteins. Currently, no reagent allows
Table 1
Human adenine nucleotide translocase genes.
ANT isoform Chromosome ATP/ADP exchange Apoptotic nature Tissue expression References
Genecard Exon number Regulatory elements
ANT1
SLC25A4
4q35 ATP export to the cytosol Pro-apoptotic Heart, skeletal muscle and brain [18,29,30,76–78]
4 CCAAT and TATA boxes
Oxidative regulatory OXBOX/REBOX
ANT2
SLC25A5
Xq24 ATP import into the matrix Anti-apoptotic Rapidly growing cells [23,24,27,28,40,55,71,79,80]
Cancer and cancer cell lines
4 TATA box, Sp1 elements (the AB boxes)
Go-1/Go-2, that bind nuclear factor 1 (NF1)
Glycolysis regulatory GRBOX
ANT3
SLC25A6
Xp22 Constant ATP export to the cytosol Pro-apoptotic Constitutively expressed in all tissues [76,81–83]
4 SP1 repeat domain; GC boxes
ANT4
SLC25A31
4q28.1 Anti-apoptotic Testis and germ cells [19,84–86]
6
564 A. Chevrollier et al. / Biochimica et Biophysica Acta 1807 (2011) 562–567satisfactory isoform-speciﬁc inhibition of ANT activity. However,
ANT1 is known to be highly expressed in differentiated tissues such as
skeletal muscle, heart and brain [18]. The major physiological role of
ANTs is the mitochondrial export of ATP and import of ADP [20]
(Table 1). The ANT3 isoform is expressed in all tissues, the expression
being correlated with the activity of oxidative metabolism [18,21–23].
Although ANT4 transcripts have been found in liver and brain tissues,
ANT4 appears to be more speciﬁc to the testis and germ cells [19].
ANT2 is speciﬁcally expressed either in undifferentiated cells, suchas
lymphocytes, or in tissues that are able to proliferate and regenerate,
such as those of the kidney and liver [18,21]. The expression of ANT2,
which has been shown to be growth-dependent [24], is considered as a
marker of cell proliferation [25]. The ANT2 gene expression is down-
regulated in differentiated cell lines and remains unexpressed, or only
slightly expressed, in most tissues [18]. Consequently, ANT2 expression
has been widely studied in cancer cells and cell lines. Unlike the ANT1
and ANT3 isoforms, ANT2 is strongly overexpressed in various types of
human cancer cells and in several hormone-dependent cancers
compared with normal human ﬁbroblasts and hepatocytes [23,26,27].
4. The ANT2 isoform is speciﬁcally involved in the glycolytic
metabolism of cancer cells
All mammals possess four ANT isoforms, ANT1-4 [24,28,29],
except for rodents in which only three isoforms have been found,
i.e. ANT1, ANT2 [30,31] and a testis isoform ANT4. Whereas Ant1−/−
mice develop mitochondrial myopathy, the disruption of ANT2 leads
to perinatal embryonic lethality [32], suggesting that the role of ANT2
is essential to the developmental process. In yeast, the mitochondrial
ADP/ATP translocase exists under three isoforms encoded by AAC1-3
[33–35]. Under aerobic conditions, the AAC1 and AAC2 proteins
ensure yeast cell growth through mitochondrial ATP synthesis and
ATP/ADP exchanges. In contrast, under anaerobic conditions, AAC3
proteins are essential for the growth of yeast on a fermentable
substrate [36]. The AAC3 gene is regulated by heme through the ROX1
factor [37], which mediates oxygen repression in several other yeast
genes [38]. This has led to the hypothesis that under anaerobic
conditions, AAC3 provides glycolytic ATP to mitochondria [39]. Thus,
in mitochondria with impaired respiration, the activity of F0F1-
ATPase is reversed such that, at the expense of ATP hydrolysis, it
contributes to the maintenance of ΔΨm at a suboptimal level by
pumping protons out of the matrix. In addition, electrogenic ATP4-
uptake versus ADP3- uptake into mitochondria completes the
maintenance of mitochondrial Δψm (Fig. 1B). When human ANT
proteins are compared to yeast AAC proteins, the yeast AAC3 and the
human ANT2 isoforms are the most closely related, with a 53%
sequence identity [40]. Comparison of the ANT2 and AAC3 proximal
promoters reveals a ROX1-like binding motif in the ANT2 promoter
region. This motif, found neither in the other human ANT genepromoters nor in the yeast AAC1 and AAC2 gene promoters, is known
as the glycolysis-regulated box (GRBOX). A yeast triple-null mutant,
in which the three AAC genes were disrupted, developed under
anaerobic conditions, when transformed with the human ANT2 cDNA
construct as opposed to the ANT3 cDNA construct [40]. In endosym-
bionts, such as Rickettsia, which are obligate intracellular parasites,
phylogenetic studies have shown that a combination of two types of
ATP/ADP translocase was involved in the switch from the glycolytic
mechanism (anoxia) to the oxidative metabolism (normoxia) [41].
This suggests that ANT2 may have kinetic properties allowing the
import of ATP into mitochondria [23] to maintain mitochondrial Δψm
and speciﬁc intra-mitochondrial anabolic pathways [42] (Fig. 1B).
Cancer cells are known to have a glycolytic phenotype that favors
cellular accumulationof intermediates suchas lactate. An increase in the
glycolyticmetabolism is associatedwithmitochondrial OxPhos damage
or inactivation due to the intrinsic conditions of transformed tumoral
cells, their undifferentiated state and their microenvironment [43–45].
In vitro studies have shown that some tumoral cell lines maintain the
ability to use their mitochondrial energetic background. Interestingly,
the expression of ANT isoforms is closely related to the energetic
metabolic properties of tumoral cells [46]. The induction of ANT2
expression in cancer cells is directly related to the higher glycolytic
metabolism whereas ANT3 is not affected [23]. Thus, undifferentiated
tumoral cell line derived from osteosarcoma overexpressing ANT2
develops in hypoxic conditions whereas the hepatocarcinoma tumoral
cell line, with a more differentiated phenotype and lower ANT2
expression, was arrested at the G1/S checkpoint [47]. Under conditions
of hypoxic stress, cell growth depends on the rapid metabolic
adaptation to decreased mitochondrial ATP production. Oxygen
deprivation leads to the arrest of the mitochondrial respiratory chain
activity, causing a collapse of the mitochondrial membrane potential
(ΔΨm), resulting in cell death. Cancer cells, which can survive a
complete OxPhos suppression by using the glycolytic metabolism [48],
dependmainly on the ATP uptake to generate theirmitochondrialΔΨm
[23]. It has been recently shown that the glycolytic phenotype in cancer
can be altered by promoting oxidative phosphorylation with dichlor-
oacetate, an inhibitor of pyruvate dehydrogenase kinase [49]. In human
non-small-cell lung cancer, glioblastomaandbreast cancer cell lines, the
use of dichloroacetate increased the production of reactive oxygen
species and decreased Δψm leading to cell death. Similarly, a highly
glycolytic cell line unable to reactivate the OxPhos metabolism was
found to be more sensitive to chloroethylnitrosourea, an anticancer
agent, as compared to a tumoral cell line conserving at least partial
mitochondrial OxPhos activity [50]. In most transformed tumoral cells,
mitochondrial ATP consumption imposes the reversal of the cellular ATP
phosphoryl pathway. ANT2 is co-expressed with hexokinase II (HK II)
and ATPsynβ, an essential subunit of mitochondrial F0F1-ATPase,
suggesting a mechanism for the regulation of ATP import [23]
(Fig. 1B). The HK II isoform was shown to be the predominantly
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conditions [47,51]. To ensure the maintenance of energetic states in
membrane-boundprocesses,most glycolytic enzymesareassociatedwith
the cytoplasmic membrane and the membranes of the intracellular
compartments [52]. Glycolytic enzymes thus contribute to intracellular
phosphoryl transfer and spatial distribution [53]. Cytoplasmic HK, which
initiates glycolysis by phosphorylating glucose to glucose-6P (G6P), is
inhibited by the product; in contrast, HK II, bound to the outside of the
mitochondrial outermembrane, is not inhibited by G6P. According to our
hypothesis, HK II,which is bound to the voltage-dependent anion channel
(VDAC) located on themitochondrial outermembrane [54] uses cytosolic
G6P to provide mitochondria with ATP through an inverse reaction.
This involves the transfer of glycolytic ATP through the VDAC and
ANT2 toward the matrix side of the mitochondrial inner membrane.
Within the inner membrane, ANT and F0F1-ATPase associate with the
inorganic phosphate carrier (PiC) to form a complex called the ATP-
synthasome [55]. This complex supports a mechanism in which the
release and exit of ATP/ADP and P(i) are highly localized and tightly
coordinated events. The imported ATPmay then be used either for the
essential intra-mitochondrial enzymatic pathways or hydrolyzed to
ADP by the F1 part of the F0F1-ATPase to maintain the ΔΨm [23].
This type of ATP hydrolysis by the reverse action of mitochondrial
F1F0-ATPase has also been associated with pathological conditions
when the respiratory chain is inhibited as in the ischemic phase of
some neurodegenerative diseases [56–58], as well as in macrophages
activated by interferon gamma and lipopolysaccharide that conse-
quently inhibit OxPhos with NO [59]. The mitochondrial import of
glycolytic ATP is essential for maintaining ΔΨm and preventing
apoptotic cell death. Since ANT2 has been reported to be up-regulated
in OxPhos-deﬁcient liver pathology [60], a detailed investigation of
the expression of ANT isoforms should prove useful in such disorders.
5. ANT isoforms play a role in cell apoptosis
The direct implication of ANT in apoptosis offers an additional
reason for focusing on ANT in cancer development. It has been shown
that ANT and members of the Bcl2-Bax family create contact sites
between the mitochondrial inner and outer membranes. ANT
cooperates with Bax, the matrix cyclophilin D (CyP-D) and the outer
membrane voltage-dependent anion channel (VDAC or porin) to form
a permeability transition pore (PTP), a lethal pore during apoptosis.
When open, this protein complex acts as a non-speciﬁc channel,
allowing molecules under 1500 Da to pass freely through the
mitochondrial inner membrane [61]. The PTP is a high-conductance,
Ca2+-activated channel modulated by a variety of pathophysiological
effectors [62,63]. Cyclosporin (Cs)A, which inhibits the matrix CyP-D
peptidyl–prolyl-cis-trans-isomerase activity, desensitizes the opening
of PTPs [64]. PTPs may open following a reduction of Δψm, leading to
complete collapse of ion/solute equilibration and secondary impair-
ment of respiration, because of the release of pyridine nucleotides and
cytochrome c, or because of substrate depletion [65]. The release of
cytochrome c into the cytosol is considered to be the key regulatory
step that irreversibly commits cells to apoptosis. While some models
suggest that cytochrome c release occurs in the absence of PTPs, being
mediated by the pro-apoptotic protein Bax, others suggest the
involvement of various components of PTPs with or without the
cooperative action of Bax [66]. The precise molecular nature of the
pore is still under debate since it was found thatmitochondria isolated
from mouse cells lacking two ANT isoforms, ANT1 and ANT2, could
still undergo CsA-sensitive, Ca2+ induced swelling, demonstrating
that the ANT is not required for this process [32]. However, the
increased capacity of mitochondria devoid of ANT to accumulate Ca2+
ions before the opening of PTPs suggests that ANT plays at best a
regulatory role in the PTP function rather than being structurally
involved in the pore assembly. The physiological response observed
implies the presence of additionalmitochondrial carriers forming poresin the mitochondrial inner membrane, so that ATP/Mg2+ or ornithine/
citrulline transportersmay alsoparticipate in the operation of PTPs [67].
Since the expression of the ANT isoforms varies according to
mitochondrial energy metabolism, these isoforms may play different
roles in the apoptotic process. Although, there is no evidence indicating
that ANT isoforms interact differently with the various members of the
Bax and Bcl2 family, the overexpression of ANT isoforms reveals
variations in apoptotic behavior. Thus, ANT1 overexpression induces
rapid cell death with a concomitant decrease in ΔΨm and subsequent
ATP depletion [68]. Similarly, the overexpression of ANT3 in HeLa cells
induces apoptosis mainly through the mitochondrial pathway [69].
Thus, the overexpression of ANT1 and ANT3 may increase ATP export
from the matrix and lead to mitochondrial de-energization inducing
apoptosis. In contrast, several converging studies indicate that theANT2
isoform is not pro-apoptotic [68,69].
Tumoral cell lines seem to support the overexpression of ANT2 as
opposed to that of ANT1 or ANT3. By favoring the import of ATP and
the so-calledmatricial conformation of ANT, the ANT2 isoformmay be
a direct inhibitor of the PTP function of ANT [70]. The maintenance of
ΔΨm is critical to drive the import of mitochondrial proteins and
control mitochondrial homeostasis. Since Bax and Bcl-2, which are
mutated or deregulated in cancer cells, contribute to neoplastic cell
proliferation by suppressing programmed cell death [65], ANT2 may
be considered as an anti-apoptotic oncoprotein that functions as an
inhibitor of mitochondrial membrane permeability.
Bearing in mind the function of ANT2, the anti-tumor strategy
targeting the ANT2 transcript should aim at inhibiting the import of
glycolytic ATP into mitochondria so as to decrease ΔΨm and increase
cancer cell apoptosis. However, HeLa cells, transiently transfected
with speciﬁc siRNA against human ANT2, showed no signiﬁcant
alteration in ΔΨm [27]. Nevertheless, in this study, the silencing of
ANT2 expression combined with the action of lonidamine, an anti-
tumor compound targeted atmitochondria that has already been used
in various cancers, decreased ΔΨm, inducing apoptotis. The syner-
gistic action of lonidamine and ANT2 depletion on ΔΨm suggests that
the exclusive reduction of the ANT2 protein expression level may not
have been sufﬁcient. In another study on human breast cancer cells,
prolonged inhibition of ANT2 expression by shRNA led to the
disruption of ΔΨm exclusively through ANT2 inhibition, inducing
apoptotic cell death [71]. In human ADF glioblastoma cells, in which
ANT2 is more abundant than ANT1, the silencing of ANT1 but not of
ANT2 by siRNA increased the oxidative stress leading to cell death. In
these astrocytic tumors, the effect of ANT1-silencing on ADF may be
mediated by the loss of the ANT1 uncoupling function [72].6. MtDNA mutations and dysregulation of ANT isoforms may lead
to neoplastic transformation
Although the mitochondrial DNA (mtDNA) encodes only a small
fraction (13/1500 proteins) of the mammalian mitochondrial pro-
teome, many mitochondrial diseases are due to mtDNA mutations or
to the failure to maintain mtDNA levels [73]. The deoxyribonucleoside
triphosphate (dNTP) pools that serve the mitochondrial genome are
synthesized primarily in the cytosol before selective import into the
matrix. The intracellular bulk of dNTP is regulated to meet the speciﬁc
metabolic demand for DNA precursors during the different phases of
the cell cycle, whereas mitochondrial DNA replication proceeds
uniformly all through the cell cycle and even during the entire
lifetime of non-cycling cells. Hence, the need for the constant
presence of precursor pools for mitochondrial DNA [74]. Mutations
in the gene encoding the ANT1 isoform-speciﬁc to the heart muscle
have been linked to progressive external ophthalmoplegia, a
condition in which mtDNA undergoes multiple deletion mutations
[75]. The concentrations of dNTPs at replication sites are important
determinants of both the rate and ﬁdelity of DNA replication. Since
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might cause an imbalance in the mutagenic dNTP pool.
Dysregulation of nucleotide biosynthesis and distribution within
the cell often results in neoplastic transformation [1]. Rapidly
proliferating cancer cells require ample, balanced supplies of nucleo-
tides for survival and growth. When this balance is perturbed, the risk
of additional DNA mutations rises, augmenting the malignant
characteristics of tumor cells. Several key enzymes involved in
nucleotide biosynthesis and modiﬁcation, including thymidylate
synthase, ribonucleotide reductase, and DNA polymerase, are mark-
edly up-regulated inmany types of cancer and therefore considered to
be promising targets for cancer therapy [1].
The dysregulation of ANT isoforms in cancer suggests that ANT
may play a role in neoplastic transformation by affecting nucleotide
metabolism and the integrity of the mitochondrial genome. In fact,
mtDNAmutations have been reported in renal adenocarcinoma, colon
cancer, astrocytic tumors, and a variety of other tumors such as those
of the head and neck, thyroid, breast and prostate [3]. MtDNA
mutations, which inhibit OxPhos activity by impeding the ﬂow of
electrons down the respiratory chain, may increase ROS production
and contribute to neoplastic transformation.
7. Conclusion
The metabolic changes following the switch from the dual
oxidative and glycolytic metabolism in normal cells to a mainly
glycolytic metabolism plays a signiﬁcant role in the survival and
proliferation of cancer cells. Further investigation of the glycolytic
phenotype, an early manifestation of carcinogenesis, should offer
novel therapeutic approaches. Thus, the silencing of ANT2 so as to
promote cell death, or the sensitization of tumoral cells to apoptotic
agents could prove useful in anticancer treatment. The chemothera-
peutic efﬁciency may depend on the capacity of cancer cells to adjust
the energy balance between glycolysis and oxidative phosphorylation.
The ANT2/ANT3 expression ratio may be used to predict whether the
up-regulation of glycolysis or the activation of OxPhos would be more
effective in maintaining mitochondrial ΔΨm. In any case, the
mitochondrial bioenergetic background of tumors should be taken
into account for the conception of individualized cancer treatments
and for the development of anticancer strategies.
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